Questionnaire for data collection
Person in charge of human xenotransplantation practice.
Title : Mr.
First Name: S.D.
Last name : Nikonov
Address :
Zip :
State : St-Petersburg
Country : Russia
Institution :
Telephone :
Email :
What is the source of your information about human xenotransplantation practices?
Publication
What is the therapeutic purpose of this xenotransplantation treatment?
pulmonary tuberculosis
Where and when is this human xenotransplantation practice taking place?
Country Russia
Timing 1990 and 1991
Is this treatment part of a clinical trial?
Yes
How many patients are included in this clinical trial?
113
What are the inclusion criteria for patient selection?
i. Duration on the waiting list? unknown
ii. Life-threatening diseases without alternative therapy? Yes
iii. Is a protocol available? No
If yes, could you please send a copy?
What is the animal source of the xenotransplantation product?
Pig
Source animals Do you have information about source animals? No
Testing of safety : Do you have information about testing of safety? No
What type of cells/tissues/organs was transplanted?
Cells:
Tissues:
Organs:
Others:
Spleen
What type of exposure to xenogeneic cells was involved?
Solid-organ xenotransplantation: No
Cellular xenotransplantation: No
Tissue xenotransplantation: No
Human cells exposed to xenogeneic Feeder cell: No
Extracorporeal perfusion: Yes
Encapsulation: No
Other bioartificial isolation device:
Others:
Transplant Do you have information about transplant recipients? No
Have results been presented at a scientific congress?
Unknown
if yes, where?
Have results been published in a scientific journal?
Yes
if yes, where?
(1) Nikonov S.D. et al. use of xenogeneic splen perfusate in the complex treatment of patients wiith destructive pulmonary tuberculosis. Probl. Tuberk. 1990;(10): 10-2. (2) Nikonov S.D. et al. Initial experience with the use of a xeno-spleen perfusate in the treatment of patients with extensive pyo-destructive diseases of the lungs and pleura. Grud. Serdechnososudistaia Khir. 1991; (2): 42-5.
Is this human clinical trial performed with governmental and/or institutional oversight and supervision?
Unknown
if yes, which?
Comment